A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes
about
Bioresorbable vascular scaffolds technology: current use and future developmentsBioresorbable scaffolds: a new paradigm in percutaneous coronary interventionBioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricksThe Safety and Efficacy of Absorb Bioresorbable Vascular Scaffold: A Systematic ReviewStent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomesBioresorbable Scaffolds: Current Evidences in the Treatment of Coronary Artery DiseaseProcedural and one-year clinical outcomes of bioresorbable vascular scaffolds for the treatment of chronic total occlusions: a single-centre experience.Everolimus-Eluting Bioresorbable Vascular Scaffold in Real World Practice - A Single Center Experience.Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users : A position statement on the use of bioresorbable vascular scaffolds in the Netherlands.Twelve or 30 months of dual antiplatelet therapy after drug-eluting stentsPrognostic significance of endothelial dysfunction in patients undergoing percutaneous coronary intervention in the era of drug-eluting stentsAngiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experienceClinical Outcomes of Bioresorbable Scaffold in Coronary Artery Disease: A Systematic Literature Review.Metallic zinc exhibits optimal biocompatibility for bioabsorbable endovascular stents.Bioresorbable Stents in PCI.Role of invasive imaging in acute and long-term assessment of bioresorbable scaffold technology.Real-life data regarding acute procedural success and 1-year clinical outcome of desolve bioresorbable scaffolds.Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.Costs and clinical outcomes for non-invasive versus invasive diagnostic approaches to patients with suspected in-stent restenosis.Biodegradable Metals for Cardiovascular Stents: from Clinical Concerns to Recent Zn-Alloys.Development of a New Hybrid Biodegradable Drug-Eluting Stent for the Treatment of Peripheral Artery Disease"Leaving nothing behind": is the bioresorbable vascular scaffold a new hope for patients with coronary artery disease?Clinical outcomes of overlapping versus non-overlapping everolimus-eluting absorb bioresorbable vascular scaffolds: An analysis from the multicentre prospective RAI registry (ClinicalTrials.gov identifier: NCT02298413).Late breaking trials of 2014 in coronary artery disease: Commentary covering ACC, EuroPCR, SCAI, TCT, ESC, and AHA.Controlling drug delivery from coronary stents: are we aiming for the right targets?Dual antiplatelet therapy, drug-eluting stents and bioresorbable vascular scaffolds: Evolutionary perspectives.Coronary Stents: The Impact of Technological Advances on Clinical Outcomes.Absorb bioresorbable stents for the treatment of coronary artery disease.The ABSORB bioresorbable vascular scaffold: A novel, fully resorbable drug-eluting stent: Current concepts and overview of clinical evidence.Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use.Biodegradable polymer stents vs second generation drug eluting stents: A meta-analysis and systematic review of randomized controlled trials.Drug-eluting stents to prevent stent thrombosis and restenosis.Intracoronary imaging of coronary atherosclerosis: validation for diagnosis, prognosis and treatment.Management of ischemic coronary disease in patients receiving chemotherapy: an uncharted clinical challenge.The year in cardiology 2015: coronary intervention.From drug eluting stents to bioresorbable scaffolds; to new horizons in PCI.Recommendations for the use of bioresorbable vascular scaffolds in percutaneous coronary interventions : 2017 revision.Bioresorbable Scaffolds for Atheroregression: Understanding of Transient ScaffoldingPercutaneous Coronary Intervention: 2015 in Review.
P2860
Q26741147-54B2C0AB-6668-4C22-8E59-06E327D0E777Q26766579-17B5FB44-2798-4644-8002-DE584B50CE9CQ26775130-5F6C6C78-6444-4C17-9FEF-F18A50ABA1B5Q26782136-3AE0E0F5-7020-42A9-A67F-CA11B5DC53FAQ26785321-3B077B62-F32F-40D0-8A00-B24B5E3B3122Q26798582-758A3FA1-55A2-4E03-8F0F-9E7B84B47E93Q28076491-8545746D-2E2A-4224-827D-FC4200C27BBBQ33612614-82458FBA-FBB7-4A89-A836-DD50BF7892B8Q33729836-CA88C2F0-666F-4E55-B9AE-C97DADB74032Q35155123-06CA4E4E-B990-4D57-BB5C-182EACBC40C8Q35783487-E9A3270F-B402-4135-9FBE-D1E329A303E7Q35785555-E15D0A50-3B99-41BA-9616-0358819B65ABQ35787354-F7F1A93E-C2E8-47DC-89BC-448C1174A477Q35884429-36524DA1-E0C7-4571-8AD5-E187C56CD7FDQ35929588-4EF62AFE-D99F-4E6D-9768-0F69270EF3CFQ36055029-3185FDAB-A8DB-4784-B2E8-F4B05599F506Q36178330-A3616417-981E-4071-82EB-671F4681E3C5Q36356024-245133FD-72A6-45DE-BFE5-396B8A62BF10Q36460858-33C8893E-289F-4DA6-843B-83424CB266F6Q36540885-362E331B-EE00-43BC-8E0E-2DA8A58AEF7FQ36996193-35138D11-0D67-454E-B68C-3E9206AA9BF7Q37483241-D49F937B-B90D-4B1A-9E6A-AA3D74739B78Q38285660-555BD852-D2E3-40AA-8483-82616156B6ABQ38376848-49DF2DB0-1058-4CFE-A5DC-F233C88464C9Q38412008-88687C66-2DCD-4F51-88E4-FEF917AC3F77Q38543392-8D0C2A06-A4A0-4159-8767-8568EC9538A7Q38563586-C5CB581A-BC23-4880-BB51-DB7EA36EE37FQ38565074-A38F422D-9020-44D1-A962-34103A2DD218Q38573540-E603EB91-091D-454E-832A-B7FE83EAEEC4Q38589504-CA7640DF-BDF3-4E96-910E-A1A3DB6D8FE2Q38592121-D32E308B-D784-4CA5-BBBA-D313C35931A4Q38620880-C33D4F67-297D-4A12-8EB9-1896A3E99E84Q38633332-905A8CD8-6643-45CE-A43B-A8A5B8608A4DQ38665986-EF9B4E46-A9F4-4592-B4EB-295265596AACQ38676248-81408202-6271-4B91-AB2F-6F4D7073F938Q38685684-72A1C978-7B30-473F-BDBB-3309FCC52602Q38702003-C6598A0F-721C-4114-9864-CD1897436881Q38712687-6FC867F7-1B18-48E9-9AA2-B953879540F3Q38714351-34B0B1C6-04DC-4AED-A648-647FC87F5DF2Q38728869-452421C2-053E-421E-B62F-1FA10EB85E29
P2860
A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A bioresorbable everolimus-elu ...... procedural secondary outcomes
@ast
A bioresorbable everolimus-elu ...... procedural secondary outcomes
@en
A bioresorbable everolimus-elu ...... native coronary artery lesions
@nl
type
label
A bioresorbable everolimus-elu ...... procedural secondary outcomes
@ast
A bioresorbable everolimus-elu ...... procedural secondary outcomes
@en
A bioresorbable everolimus-elu ...... native coronary artery lesions
@nl
prefLabel
A bioresorbable everolimus-elu ...... procedural secondary outcomes
@ast
A bioresorbable everolimus-elu ...... procedural secondary outcomes
@en
A bioresorbable everolimus-elu ...... native coronary artery lesions
@nl
P2093
P1433
P1476
A bioresorbable everolimus-elu ...... procedural secondary outcomes
@en
P2093
Andres Iniguez
Angel Cequier
Bernard Chevalier
Didier Carrié
Hector M Garcia-Garcia
Luc Wasungu
Maik J Grundeken
Marcello Dominici
Michael Haude
P356
10.1016/S0140-6736(14)61455-0
P407
P577
2014-09-14T00:00:00Z